PT  - JOURNAL ARTICLE
AU  - W. Alton Russell
AU  - Eduard Grebe
AU  - Brian Custer
TI  - Factors driving availability of COVID-19 convalescent plasma: Insights from a demand, production and supply model
AID  - 10.1101/2020.10.25.20219170
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.25.20219170
4099  - http://medrxiv.org/content/early/2020/10/27/2020.10.25.20219170.short
4100  - http://medrxiv.org/content/early/2020/10/27/2020.10.25.20219170.full
AB  - Background COVID-19 Convalescent Plasma (CCP) is a promising treatment for COVID-19. Blood collectors have rapidly scaled up collection and distribution programs.Methods We developed a detailed simulation model of CCP donor recruitment, collection, production and distribution processes. Simulations based on epidemics in 11 U.S. states, in which key parameters were varied over wide ranges, allowed identification of the drivers of ability to calibrate collections capacity and ability to meet demand for CCP.Results Changes in collection capacity utilization lagged increases and decreases in COVID-19 hospital discharges, and never exceeded 75% in most simulations. Demand could be met for most of the simulation period in most simulations, but in states with early sharp increases in hospitalizations a substantial portion of demand went unmet during these early peaks. Modeled second wave demand could generally be met with stockpiles established during first epidemic peaks. Apheresis machine capacity (number of machines) and probability that COVID-19 recovered individuals are willing to donate were the most important supply-side drivers of ability to meet demand. Recruitment capacity was important in states with early peaks.Conclusions Epidemic trajectory was the most important determinant of ability to meet demand for CCP, although our simulations revealed several contributing operational drivers of CCP program success.Competing Interest StatementW.A.R. and B.C. have provided consulting services outside the submitted work for Terumo BCT, a manufacturer of apheresis equipment.Funding StatementThis work was funded by Vitalant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe have shared all code and data in a public repository except for the individual donor return data. https://doi.org/10.5281/zenodo.4082755. https://doi.org/10.5281/zenodo.4082755 https://github.com/vitalantri/ccp_model